The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
The Impact of Hemolysis on Cell-Free microRNA Biomarkers
Open accessAbstract
Cell-free microRNAs in plasma and serum have become a promising source of biomarkers for various diseases. Despite rapid progress in this field, there remains a lack of consensus regarding optimal quantification methods, reference genes, and quality control of samples. Recent studies have shown that hemolysis occurring during blood collection has substantial impact on the microRNA content in plasma/serum. To date, the impact of hemolysis has only been investigated for a limited number of microRNAs, mainly the red blood cell (RBC)-enriched miRs-16 and -451. In contrast, the effect of hemolysis on other microRNAs - in particular those proposed as biomarkers - has not been addressed. In this study we profiled the microRNA content of hemolyzed and non-hemolyzed plasma as well as RBCs to obtain a profile of microRNAs in the circulation affected or unaffected by hemolysis. Profiling by TaqMan Array Microfluidic Cards was used to compare three pairs of hemolyzed and non-hemolyzed plasma (with varying degrees of hemolysis) and one RBC sample. A total of 136 microRNAs were detectable in at least two of the samples, and of those 15 were at least twofold elevated in all three hemolyzed samples. This number increased to 88 microRNAs for the sample with the highest level of hemolysis, with all of these also detected in the RBC profile. Thus these microRNAs represent a large proportion of detectable microRNAs and those most likely to be affected by hemolysis. Several of the hemolysis-susceptible microRNAs (e.g., miRs-21, -106a, -92a, -17, -16) have also been previously proposed as plasma/serum biomarkers of disease, highlighting the importance of rigorous quality control of plasma/serum samples used for measurement of circulating microRNAs. As low-level hemolysis is a frequent occurrence during plasma/serum collection it is critical that this is taken into account in the measurement of any candidate circulating microRNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
Characterization of extracellular circulating microRNA
Turchinovich, A., Weiz, L., Langheinz, A., & Burwinkel, B. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr254 · Cited by 1,941
Circulating MicroRNAs in Patients With Coronary Artery Disease
Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., Liebetrau, C., Weber, M., Hamm, C. W., Röxe, T., Müller-Ardogan, M., et al. (2010) · Circulation Research · doi:10.1161/circresaha.109.215566 · Cited by 1,233
Ng, E. K. O., Chong, W. W. S., Jin, H., Lam, E. K. Y., Shin, V. Y., Yu, J., Poon, T. C. W., Ng, S. S. M., & Sung, J. J. Y. (2009) · Gut · doi:10.1136/gut.2008.167817 · Cited by 1,151
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis
Kosaka, N., Iguchi, H., & Ochiya, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01650.x · Cited by 1,147
Circulating MicroRNAs: Novel Biomarkers and Extracellular Communicators in Cardiovascular Disease?
Creemers, E. E., Tijsen, A. J., & Pinto, Y. M. (2012) · Circulation Research · doi:10.1161/circresaha.111.247452 · Cited by 1,009
Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
Huang, Z., Huang, D., Ni, S., Peng, Z., Sheng, W., & Du, X. (2010) · International Journal of Cancer · doi:10.1002/ijc.25007 · Cited by 964
Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
Pritchard, C. C., Kroh, E., Wood, B., Arroyo, J. D., Dougherty, K. J., Miyaji, M. M., Tait, J. F., & Tewari, M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0370 · Cited by 879
Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer
Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181cc939f · Cited by 687
Assessing sample and miRNA profile quality in serum and plasma or other biofluids
Blondal, T., Jensby Nielsen, S., Baker, A., Andreasen, D., Mouritzen, P., Wrang Teilum, M., & Dahlsveen, I. K. (2013) · Methods · doi:10.1016/j.ymeth.2012.09.015 · Cited by 687
Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges
McDonald, J. S., Milosevic, D., Reddi, H. V., Grebe, S. K., & Algeciras-Schimnich, A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.157198 · Cited by 679
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
Zhou, J., Yu, L., Gao, X., Hu, J., Wang, J., Dai, Z., Wang, J.-F., Zhang, Z., Lu, S., Huang, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2697 · Cited by 635
Circulating microRNAs in plasma of patients with gastric cancers
Tsujiura, M., Ichikawa, D., Komatsu, S., Shiozaki, A., Takeshita, H., Kosuga, T., Konishi, H., Morimura, R., Deguchi, K., Fujiwara, H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605608 · Cited by 628
Collino, F., Deregibus, M. C., Bruno, S., Sterpone, L., Aghemo, G., Viltono, L., Tetta, C., & Camussi, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011803 · Cited by 608
Haemolysis during sample preparation alters microRNA content of plasma
Kirschner, M. B., Kao, S. C., Edelman, J. J., Armstrong, N. J., Vallely, M. P., van Zandwijk, N., & Reid, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024145 · Cited by 569
Self-citationWang, J., Chen, J., Chang, P., LeBlanc, A., Li, D., Abbruzzesse, J. L., Frazier, M. L., Killary, A. M., & Sen, S. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0094 · Cited by 559
Circulating microRNAs: Association with disease and potential use as biomarkers
Reid, G., Kirschner, M. B., & van Zandwijk, N. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.11.004 · Cited by 467
Self-citationMicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases
Cortez, M. A., & Calin, G. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902932889 · Cited by 436
Serum microRNAs as non-invasive biomarkers for cancer
Brase, J. C., Wuttig, D., Kuner, R., & Sültmann, H. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-306 · Cited by 421
Plasma MicroRNA-122 as a Biomarker for Viral-, Alcohol-, and Chemical-Related Hepatic Diseases
Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., Fei, M., & Sun, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147850 · Cited by 415
Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures
Duttagupta, R., Jiang, R., Gollub, J., Getts, R. C., & Jones, K. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020769 · Cited by 307
Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients
Tanaka, M., Oikawa, K., Takanashi, M., Kudo, M., Ohyashiki, J., Ohyashiki, K., & Kuroda, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005532 · Cited by 298
Circulating micro‐RNA expression profiles in early stage nonsmall cell lung cancer
Heegaard, N. H. H., Schetter, A. J., Welsh, J. A., Yoneda, M., Bowman, E. D., & Harris, C. C. (2012) · International Journal of Cancer · doi:10.1002/ijc.26153 · Cited by 288
Human Traumatic Brain Injury Alters Plasma microRNA Levels
Redell, J. B., Moore, A. N., Ward, N. H., Hergenroeder, G. W., & Dash, P. K. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2010.1481 · Cited by 282
Plasma MiR-21: A Potential Diagnostic Marker of Colorectal Cancer
Kanaan, Z., Rai, S. N., Eichenberger, M. R., Roberts, H., Keskey, B., Pan, J., & Galandiuk, S. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318265bd6f · Cited by 269
Use of Circulating MicroRNAs to Diagnose Acute Myocardial Infarction
Devaux, Y., Vausort, M., Goretti, E., Nazarov, P. V., Azuaje, F., Gilson, G., Corsten, M. F., Schroen, B., Lair, M.-L., Heymans, S., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.173823 · Cited by 265
Li, B.-S., Zhao, Y.-L., Guo, G., Li, W., Zhu, E.-D., Luo, X., Mao, X.-H., Zou, Q.-M., Yu, P.-W., Zuo, Q.-F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041629 · Cited by 242
Hematopoietic-specific microRNA expression in human cells
Ramkissoon, S. H., Mainwaring, L. A., Ogasawara, Y., Keyvanfar, K., Philip McCoy, J., Sloand, E. M., Kajigaya, S., & Young, N. S. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.09.001 · Cited by 242
Lechner, K., & Obermeier, H. L. (2012) · Medicine · doi:10.1097/md.0b013e3182603598 · Cited by 235
Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis
Bruchova, H., Yoon, D., Agarwal, A. M., Mendell, J., & Prchal, J. T. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.021 · Cited by 214
Circulating miR-210 Predicts Survival in Critically Ill Patients with Acute Kidney Injury
Lorenzen, J. M., Kielstein, J. T., Hafer, C., Gupta, S. K., Kümpers, P., Faulhaber-Walter, R., Haller, H., Fliser, D., & Thum, T. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00430111 · Cited by 204
Konishi, H., Ichikawa, D., Komatsu, S., Shiozaki, A., Tsujiura, M., Takeshita, H., Morimura, R., Nagata, H., Arita, T., Kawaguchi, T., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.588 · Cited by 201
Ali, S. S., Almhanna, K., Chen, W., Philip, P. A., & Sarkar, F. H. (2010) · PubMed · Cited by 199
The role of microRNAs in normal and malignant hematopoiesis
Vasilatou, D., Papageorgiou, S., Pappa, V., Papageorgiou, E., & Dervenoulas, J. (2010) · European Journal of Haematology · doi:10.1111/j.1600-0609.2009.01348.x · Cited by 189
Cell-free Circulating miRNA Biomarkers in Cancer
Mo, M.-H., Chen, L., Fu, Y., Wang, W., & Fu, S. W. (2012) · Journal of Cancer · doi:10.7150/jca.4919 · Cited by 179
Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis
Jia, S.-Z., Yang, Y., Lang, J., Sun, P., & Leng, J. (2013) · Human Reproduction · doi:10.1093/humrep/des413 · Cited by 172 · cited 1×
“miR-17 Endometriosis Down (compared to healthy) Jia et al. (2013) Yes”
BackgroundLu, T. X., Sherrill, J. D., Wen, T., Plassard, A. J., Besse, J. A., Abonia, J. P., Franciosi, J. P., Putnam, P. E., Eby, M., Martin, L. J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.01.060 · Cited by 165
Tissue‐ and Plasma‐Specific MicroRNA Signatures for Atherosclerotic Abdominal Aortic Aneurysm
Kin, K., Miyagawa, S., Fukushima, S., Shirakawa, Y., Torikai, K., Shimamura, K., Daimon, T., Kawahara, Y., Kuratani, T., & Sawa, Y. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.000745 · Cited by 163
The role of microRNAs in normal and malignant hematopoiesis
Kuchenbauer, F. (2017) · Cited by 154
Microangiopathic Hemolytic Anemia in Metastatic Carcinoma
Lohrmann, H., ADAM, W., HEYMER, B., & KUBANEK, B. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-3-368 · Cited by 153
Circulating miR-17-5p and miR-20a: Molecular markers for gastric cancer
Xu, W. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.828 · Cited by 141
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma
Jones, C. I., Zabolotskaya, M. V., King, A. J., Helen, S., Horne, G. A., Chevassut, T. J. T., & Newbury, S. F. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.525 · Cited by 139
Analytical challenges and technical limitations in assessing circulating MiRNAs
Mayr, M., & Zampetaki, A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-02-0097 · Cited by 139
Kirschner, M. B., Cheng, Y. Y., Badrian, B., Kao, S., Creaney, J., Edelman, J. J., Armstrong, N. J., Vallely, M. P., Musk, A. W., Robinson, B. W. S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182572e83 · Cited by 136
Self-citationTang, D., Shen, Y., Wang, M., Yang, R., Wang, Z., Sui, A., Jiao, W., & Wang, Y. (2013) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e32835f3be9 · Cited by 135
Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
Santarelli, L., Strafella, E., Staffolani, S., Amati, M., Emanuelli, M., Sartini, D., Pozzi, V., Carbonari, D., Bracci, M., Pignotti, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018232 · Cited by 115
Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients
Tomasetti, M., Staffolani, S., Nocchi, L., Neužil, J., Strafella, E., Manzella, N., Mariotti, L., Bracci, M., Valentino, M., Amati, M., et al. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.02.009 · Cited by 115
Zuo, Z., Calin, G. A., de Paula, H. M., Medeiros, L. J., Fernandez, M. H., Shimizu, M., Garcia‐Manero, G., & Bueso-Ramos, C. (2011) · Blood · doi:10.1182/blood-2011-01-330704 · Cited by 105
Weber, D. G., Johnen, G., Bryk, O., Jöckel, K., & Brüning, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030221 · Cited by 97
Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma
Ohyashiki, K., Umezu, T., Yoshizawa, S., Ito, Y., Ohyashiki, M., Kawashima, H., Tanaka, M., Kuroda, M., & Ohyashiki, J. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016408 · Cited by 91
Influence of short-term venous stasis on clinical chemistry testing
Lippi, G., Salvagno, G. L., Montagnana, M., Brocco, G., & Guidi, G. C. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.146 · Cited by 81
Liu, R., Liao, J., Yang, M., Shi, Y., Peng, Y., Wang, Y., Pan, E., Guo, W., Pu, Y., & Yin, L. (2012) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2012.699856 · Cited by 79
Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
Yoshizawa, S., Ohyashiki, J. H., Ohyashiki, M., Umezu, T., Suzuki, K., Inagaki, A., Iida, S., & Ohyashiki, K. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2011.51 · Cited by 75
Lu, Z.-D., YE, Y., Jiao, D., QIAO, J., Cui, S., & Liu, Z. (2012) · Oncology Letters · doi:10.3892/ol.2012.841 · Cited by 62
Lippi, G., Salvagno, G. L., Favaloro, E. J., & Guidi, G. C. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.132 · Cited by 54
Human Red Blood Cells: Rheological Aspects, Uptake, and Release of Cytotoxic Drugs
Dumez, H., Reinhart, W. H., Guetens, G., & de Bruijn, E. A. (2004) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360490452031 · Cited by 34
Phlebotomy site haemolysis rates vary inversely with workload
Hawkins, R. C. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.224 · Cited by 12
Cited by
Cheng, L., Sharples, R. A., Scicluna, B. J., & Hill, A. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.23743 · Cited by 715
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409
Circulating biomarkers for early detection and clinical management of colorectal cancer
Marcuello, M., Vymetalkova, V., Neves, R. P. L., Duran-Sanchon, S., Vedeld, H. M., Tham, E., van Dalum, G., Flügen, G., Garcia-Barberan, V., Fijneman, R. J., et al. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.06.002 · Cited by 275
Challenges in Using Circulating miRNAs as Cancer Biomarkers
Tiberio, P., Callari, M., Angeloni, V., Daidone, M. G., & Appierto, V. (2015) · BioMed Research International · doi:10.1155/2015/731479 · Cited by 271
Shah, J. S., Soon, P. S., & Marsh, D. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153200 · Cited by 216
“Similarly, Kirschner et al. (2013) suggested use of absorbance at 414 nm>0.2 (unhemolyzed plasma as blank) to identify hemolysis in plasma as it reduced variability in miR-451 levels [23].”
BackgroundInfluential
Metadata
- Authors
- Kirschner, M. B., Edelman, J. J. B., Kao, S. C.-H., Vallely, M. P., van Zandwijk, N., & Reid, G.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 94-94
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2012913468
- Cited by
- 352
- References
- 63
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.